Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)

Abstract

Lepodisiran reduced mean serum concentrations of lipoprotein(a) from 60 to 180 days after administration. (Funded by Eli Lilly; ALPACA ClinicalTrials.gov number, NCT05565742.).